In a small study, approximately a third of kidney transplant recipients had anemia and half had persistent secondary hyperparathyroidism.
Booster shots have become a hot topic since Pfizer-BioNTech said last week it would seek EUA for a third shot of its 2-dose vaccine
Therapies used to treat COVID-19 in solid organ transplant recipients shifted since the pandemic began
Favorable outcomes, minimal adverse effects seen in solid organ transplant recipients who received monoclonal antibody therapy for COVID-19.
Between 2014 and 2021, 250 family voucher-based donations facilitated 573 total transplants
Delays in waitlisting can result in some patients losing their priority status for high-quality deceased donor kidneys with the lowest risk of failure.
In a case series, SARS-CoV-2 antibody titers increased after the third dose in a third of patients who previously had no response to vaccination.
Findings support COVID-19 vaccination of patients on dialysis but suggest that a shift in vaccine strategy for kidney transplant recipients may be warranted.
A study of patients who initiated dialysis in the Southeast United States found that those receiving care at for-profit facilities were 16% less likely to receive a kidney transplant referral than patients at non-profit facilities.
Patients with moderate and severe infection experienced a 17.50% and 23.16% decrease in estimated glomerular filtration rate (eGFR), respectively, from baseline (before testing positive for SARS-CoV-2) to 90 days after the positive test.